![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/06/17/2899626/0/en/Inhibikase-Therapeutics-Completes-Enrollment-of-the-Phase-2-201-Trial-Evaluating-Risvodetinib-in-Untreated-Parkinson-s-Disease.html
https://www.globenewswire.com//news-release/2024/03/07/2842246/0/en/Inhibikase-Therapeutics-to-Provide-Trial-Update-for-Risvodetinib-at-the-2024-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-and-Related-Neurological-Disorders.html
https://www.globenewswire.com/news-release/2024/01/29/2818972/0/en/Inhibikase-Therapeutics-Announces-Publication-Highlighting-Results-from-its-Phase-1-Studies-with-Risvodetinib.html
https://www.globenewswire.com//news-release/2023/10/16/2760510/0/en/Inhibikase-Therapeutics-Highlights-Unblinded-Functional-Analysis-from-the-201-Trial-of-Risvodetinib-in-Untreated-Parkinson-s-Disease-and-Provides-Update-on-Ongoing-Enrollment.html
https://www.globenewswire.com//news-release/2023/10/04/2754577/0/en/Inhibikase-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-Risvodetinib-for-the-Treatment-of-Multiple-System-Atrophy.html